IP Library Granted Patent US 8,609,646
Granted Patent B2
US 8,609,646 · App. 12/804,029 · Granted Dec 17, 2013

Enhanced erythropoiesis and iron metabolism

Inventors: Stephen J. Klaus (San Francisco, CA); Christopher J. Molineaux (San Francisco, CA); Thomas B. Neff (Atherton, CA); Volkmar Guenzler-Pukall (San Leandro, CA); Ingrid Langsetmo Parobok (Port Angeles, WA); Todd W. Seeley (Moraga, CA); Robert C. Stephenson (Foster City, CA)
Assignee: Fibrogen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,609,646
App. No.
12/804,029
Granted
Dec 17, 2013
Kind
B2
Abstract

The present invention relates to methods and compounds for decreasing the expression of hepcidin, a protein associated with regulation of iron metabolism.

Claims (9)

1. A method for decreasing hepcidin expression in a subject in need thereof, the method comprising administering to the subject an effective amount of a heterocyclic carboxamide compound that stabilizes the alpha subunit of hypoxia-inducible factor (HIFα), thereby decreasing hepcidin expression in the subject.

2. The method of claim 1 , wherein the heterocyclic carboxamide compound is a heterocyclic carbonyl glycine compound.

3. The method of claim 1 , wherein the subject is a subject having anemia.

4. The method of claim 3 , wherein the anemia is anemia of chronic disease.

5. The method of claim 1 , wherein the subject is a subject having a chronic disease selected from the group consisting of an inflammation, an infection, an immunodeficiency disorder, and a neoplastic disorder.

6. The method of claim 1 , wherein the subject is a subject having iron deficiency.

7. The method of claim 6 , wherein the iron deficiency is functional iron deficiency.

8. The method of claim 1 , wherein the heterocyclic carboxamide compound inhibits hypoxia-inducible factor prolyl hydroxylase enzyme activity.

9. The method of claim 1 , wherein the heterocyclic carboxamide compound is a structural mimetic of 2-oxoglutarate.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 3, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: FIBROGEN, INC.
Reel/Frame 072785/0760 →
SECURITY INTEREST Recorded May 1, 2023
From: FIBROGEN, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 063504/0221 →
CHANGE OF ADDRESS Recorded Oct 31, 2013
From: FIBROGEN, INC.
To: FIBROGEN, INC.
Reel/Frame 031526/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2013
From: KLAUS, STEPHEN J.; MOLINEAUX, CHRISTOPHER J.; NEFF, THOMAS B.; GUENZLER-PUKALL, VOLKMAR; PAROBOK, INGRID LANGSETMO; SEELEY, TODD W.; STEPHENSON, ROBERT C.
To: FIBROGEN, INC.
Reel/Frame 031500/0954 →
Continuity (6)
Division 10861590 · Jun 3, 2004
Provisional Application 60569797 · May 10, 2004
Provisional Application 60566488 · Apr 29, 2004
Provisional Application 60566237 · Apr 29, 2004
Provisional Application 60476704 · Jun 6, 2003
Related Publication 20100280044A1 · Nov 4, 2010